{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:11:21Z","timestamp":1782515481809,"version":"3.54.5"},"reference-count":46,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T00:00:00Z","timestamp":1282089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p> <jats:italic>Please cite this paper as:<\/jats:italic> Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010;117:1475\u20131484.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease (uPID) in Asia.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Prospective, randomised, double\u2010blind, double\u2010dummy, parallel\u2010group study.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Multicentre, multinational study in the inpatient and\/or outpatient setting.<\/jats:p><jats:p><jats:bold>Population\u2002<\/jats:bold> Women (aged \u226518\u2003years) with uPID (defined as PID with no pelvic or tubo\u2010ovarian abscess on pelvic ultrasonography and at laparoscopic examination) and not requiring intravenous treatment.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Women received a 14\u2010day course of either oral moxifloxacin, 400\u2003mg once daily, or oral levofloxacin, 500\u2003mg once daily, plus oral metronidazole, 500\u2003mg twice daily. Additionally, a single dose of ceftriaxone, 250\u2003mg intramuscularly, was administered to women who had a positive screening test for <jats:italic>Neisseria gonorrhoeae<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> The primary measure of efficacy was clinical response at test\u2010of\u2010cure (TOC) (7\u201314\u2003days after the last dose of study drug) in the per\u2010protocol population. Noninferiority of moxifloxacin to the comparator regimen was demonstrated if lower limit of 95% CI was &gt;\u221215%. Other measures were clinical response during therapy and at 4\u2010week follow up, microbiological response at TOC, and safety.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 460 women were randomised to the study. For the primary measure of efficacy (clinical cure at TOC), moxifloxacin was noninferior to levofloxacin plus metronidazole (moxifloxacin: 152\/194, 78.4%; comparator 155\/190, 81.6%; 95% CI \u221210.7 to +4.9). The most commonly isolated pathogens at baseline included <jats:italic>Neisseria gonorrhoeae<\/jats:italic>, <jats:italic>Chlamydia trachomatis<\/jats:italic>, <jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Staphylococcus aureus<\/jats:italic>, <jats:italic>Peptostreptococcus<\/jats:italic> spp., <jats:italic>Proteus mirabilis<\/jats:italic>, <jats:italic>Streptococcus agalactiae<\/jats:italic> and <jats:italic>Klebsiella pneumoniae<\/jats:italic>. Bacteriological success rates were high and comparable between treatment arms (microbiologically valid populations, moxifloxacin 27\/30, 90.0%; comparator 22\/26, 84.6%; 95% CI \u221212.7 to +20.3). Both treatments were well tolerated.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Moxifloxacin monotherapy, 400\u2003mg once daily for 14\u2003days, is an effective and well\u2010tolerated oral treatment for women with uPID.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2010.02687.x","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T16:28:42Z","timestamp":1282148922000},"page":"1475-1484","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study"],"prefix":"10.1111","volume":"117","author":[{"given":"P","family":"Judlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Reimnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Arvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462991914447"},{"key":"e_1_2_12_3_2","unstructured":"National Survey of Family Growth; Vital and Health Statistics.Hyattsville (MD): US Department of Health and Human Services Public Health Service National Center for Health Statistics.1995. [http:\/\/www.cdc.gov\/nchs\/data\/series\/sr_23\/sr23_025.pdf]. Accessed 27 July 2010."},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7287.658"},{"key":"e_1_2_12_5_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2006","volume":"55","author":"Workowski KA","year":"2006","journal-title":"MMWR"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646207782193911"},{"key":"e_1_2_12_7_2","first-page":"53","article-title":"Laparoscopic versus clinical diagnosis of acute pelvic inflammatory disease","volume":"38","author":"Morcos R","year":"1993","journal-title":"J Reprod Med"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2005.019109"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02118-X"},{"issue":"2","key":"e_1_2_12_10_2","first-page":"S32","article-title":"Sexually transmitted diseases and infertility","volume":"21","author":"Westrom LV","year":"1994","journal-title":"Sex Transm Dis"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(11)90790-X"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.121625"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006205-199702000-00006"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000303100108"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/154099904323016446"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/512191"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199306000-00002"},{"key":"e_1_2_12_18_2","unstructured":"Centers for Disease Control and Prevention (CDC).Sexually transmitted diseases. Treatment guidelines 2006. Updated recommendations April2007. [http:\/\/www.cdc.gov\/STD\/treatment\/2006\/pid.htm]. Accessed 27 July 2010."},{"key":"e_1_2_12_19_2","volume-title":"Management of Acute Pelvic Inflammatory Disease. 2008","author":"Royal College of Obstetricians and Gynaecologists","year":"2008"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2008.008495"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2060"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2793"},{"key":"e_1_2_12_23_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/AAC.41.3.709","article-title":"Comparison of the in vitro activities of Bay 12\u20108039, a new quinolone, and other antimicrobials against clinically important anaerobes","volume":"41","author":"Aldridge KE","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.101"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.6.825"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02027.x"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/anae.2000.0360"},{"key":"e_1_2_12_28_2","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-197710000-00001"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2003.tb05627.x"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646202760159710"},{"key":"e_1_2_12_32_2","first-page":"595","article-title":"Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline","volume":"71","author":"Wolner\u2010Hanssen P","year":"1988","journal-title":"Obstet Gynecol"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)91479-G"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.8.1651"},{"key":"e_1_2_12_35_2","first-page":"1","article-title":"Pelvic inflammatory disease: guidelines for prevention and management","volume":"40","author":"Centers for Disease Control and Prevention","year":"1991","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1363\/3713505"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.162.11.1022"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl265"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/511422"},{"key":"e_1_2_12_40_2","first-page":"48","article-title":"Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006","volume":"32","author":"Tapsall JW","year":"2008","journal-title":"Commun Dis Intell"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646206775220469"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646206779307595"},{"key":"e_1_2_12_43_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/OLQ.0b013e3180ca8f24","article-title":"Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999\u20132006","volume":"34","author":"Su X","year":"2007","journal-title":"Sex Transm Dis"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.08.029"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328334de21"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932050-00001"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90170-1"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2010.02687.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2010.02687.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:58:53Z","timestamp":1698721133000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2010.02687.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1471-0528.2010.02687.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2010.02687.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,18]]},"assertion":[{"value":"2010-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}